GeoVax Highlights MVA Platform for Bundibugyo Ebola and Schedules Q4 2026 Phase 3
GeoVax noted that the Bundibugyo Ebola strain currently has no approved vaccine and stressed its MVA-based platform’s capacity for rapid adaptation, multivalent antigen incorporation, and established safety profile. The company will launch a pivotal Phase 3 immunobridging study of its GEO-MVA mpox/smallpox candidate in Q4 2026, with data expected three months later.
1. Bundibugyo Ebola Outbreak Exposes Vaccine Gaps
The current Bundibugyo Ebola outbreak involves a species for which no broadly approved vaccine exists, underscoring limitations of strain-specific preparedness. GeoVax emphasized that continuous emergence of diverse high-consequence pathogens demands adaptable vaccine technologies with scalable manufacturing and flexible antigen design.
2. MVA Platform Advantages and GEO-MVA Phase 3 Plans
GeoVax detailed that its Modified Vaccinia Ankara (MVA) platform offers established safety, multivalent antigen incorporation, cross-family applicability, rapid adaptability, and potential for single-dose multivalent vaccines. The company plans to initiate a pivotal Phase 3 immunobridging trial of GEO-MVA for mpox and smallpox in Q4 2026, aiming to deliver results within three months of initiation.